Fig. 5

CB-1158-treated animals have increased tumor-infiltrating cytotoxic cells and decreased myeloid cells. a CT26 tumors from animals treated with CB-1158 had increased CD8⁺ CD25⁺ T cells as determined by flow cytometry compared to vehicle-treated animals on study day 14 (N = 10 per group). b In the B16 model, CB-1158 treatment resulted in an increase in CD25⁺ CD8⁺ T cells observed on study day 9 (N = 10 per group). c In the LLC model, CB-1158 treatment resulted in increased tumor infiltrating CD8⁺ T cells and decreased CD68⁺ myeloid cells observed on study day 14 (N = 10 per group). d In the 4T1 model, CB-1158 treatment resulted in increases in both T cells and NK cells and a decrease in myeloid cells observed on study day 10 (N = 10 per group). e CB-1158 increases T cell and NK cell markers and interferon response genes. mRNA transcripts in LLC tumors from mice treated with vehicle or 100 mg/kg CB-1158 twice daily were determined by Nanostring (N = 6 per group). f Cytokines and chemokines in LLC tumors from mice treated with vehicle or 200 mg/kg CB-1158 twice daily were determined by Luminex (N = 5 per group). (T test: ** P < 0.01; * P < 0.05)